Αρχική World News EMA Recommends Granting a Marketing Authorisation for Poherdy World News EMA Recommends Granting a Marketing Authorisation for Poherdy Από Ogkologos - 10 Απριλίου, 2026 279 0 Facebook Twitter Google+ Pinterest WhatsApp It is a biosimilar of pertuzumab which was authorised in the EU in 2013 Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Geriatric Assessment Intervention Reduces Patient-Reported Symptomatic Toxicities in Older Patients with... 17 Νοεμβρίου, 2022 Five Questions With…Jim. 28 Απριλίου, 2022 Phytochemicals and Antioxidants 11 Δεκεμβρίου, 2020 When Cancer Spreads to Bone, A Single Dose of Radiation Therapy... 21 Μαΐου, 2019 Φόρτωση περισσοτέρων HOT NEWS 120 years of discovery: 10 ways we’ve changed the story for... What to Know About Biomarker Testing for Lung Cancer: An Expert... EMA Recommends Extension of Indications for Durvalumab EMA Recommends a Change to the Terms of the Marketing Authorisation...